drugset / Trial / NCT01698931

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

NCT01698931

Phase 4 Completed 9 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to compare the efficacy of repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2 diabetes.

Timeline

Start
2002-04-26
Primary completion
2003-03-06
Completion
2003-03-06

Publications

  • Results Ciccarone A, Mari A, Pulizzi N, Bianchi C, Palumbo F, Benzi L, Del Prato S. Assessment of insulin secretion in response to a mixed meal in type 2 diabetes. Effects of short-term repaglinide and glibenclamide administration. Diabetologia 2005; 48 (Suppl. 1): A284 (Abstract No. PS65-781)

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyburide Small molecule 5 mg
Subject Repaglinide Small molecule 1 mg